Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar

Aspirin Inclusion in Antipsychotic Treatment on Severity of Symptoms in Schizophrenia: A Randimized Clinical Trial

Abbas Attari 1 , Asefeh Mojdeh 2 , * , Fakhri Al Sadat Khalifeh Soltani 3 and Mohammad Reza Najarzadegan 4
Authors Information
1 Behavioral Sciences Research Center, Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Psychiatry, Iran University of Medical Sciences, Tehran, Iran
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: March 2017, 11 (1); e5848
  • Published Online: December 4, 2016
  • Article Type: Original Article
  • Received: March 3, 2016
  • Revised: August 12, 2016
  • Accepted: November 18, 2016
  • DOI: 10.5812/ijpbs.5848

To Cite: Attari A, Mojdeh A, Khalifeh Soltani F A S, Najarzadegan M R. Aspirin Inclusion in Antipsychotic Treatment on Severity of Symptoms in Schizophrenia: A Randimized Clinical Trial, Iran J Psychiatry Behav Sci. 2017 ;11(1):e5848. doi: 10.5812/ijpbs.5848.

Abstract
Copyright © 2016, Mazandaran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Sadock B, Sadock V. Behavioral Sciences/Clinical Psychiatry. 2010; : 1-43
  • 2. Diagnostic and statistical manual of mental disorders. 2000;
  • 3. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010; 71(9): 1115-24[DOI][PubMed]
  • 4. Oken RJ, Schulzer M. At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr Bull. 1999; 25(4): 625-38[PubMed]
  • 5. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002; 159(6): 1029-34[DOI][PubMed]
  • 6. Muller N, Myint AM, Schwarz MJ. Inflammation in schizophrenia. Adv Protein Chem Struct Biol. 2012; 88: 49-68[DOI][PubMed]
  • 7. Jones J. Can Aspirin Treat Schizophrenia? 2010;
  • 8. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988; 23(1): 99-110[DOI][PubMed]
  • 9. Kozielska M, Pilla Reddy V, Johnson M, de Ridder F, Vermeulen A, Liu J, et al. Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia. Schizophr Res. 2013; 146(1-3): 53-8[DOI][PubMed]
  • 10. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010; 71(5): 520-7[DOI][PubMed]
  • 11. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006; 32(2): 214-9[DOI][PubMed]
  • 12. Murphy BP, Chung YC, Park TW, McGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res. 2006; 88(1-3): 5-25[DOI][PubMed]
  • 13. Sommer IE, de Witte L, Begemann M, Kahn RS. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012; 73(4): 414-9[DOI][PubMed]
  • 14. Muller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res. 2010; 121(1-3): 118-24[DOI][PubMed]
  • 15. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007; 90(1-3): 179-85[DOI][PubMed]
  • 16. Laan W, Selten JP, Kahn RS, Huisman AM, Heijnen CJ, Grobbee DE, et al. Acetylsalicylic acid as an adjuvant therapy for schizophrenia. Trials. 2006; 7: 31[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments